Ligand’s Second Quarter Financial Results to be Reported August 3rd
July 16 2020 - 4:28PM
Business Wire
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
provided today details of its plans to report second quarter 2020
financial results on August 3, 2020. Ligand’s CEO John Higgins,
President and COO Matt Foehr, and Executive Vice President and CFO
Matt Korenberg will host the conference call.
Second Quarter 2020 Earnings Conference Call
What:
Ligand conference call to discuss
financial results and provide general business updates
Date:
Monday, August 3, 2020
Time:
8:30 a.m. Eastern time (5:30 a.m. Pacific
time)
Conference Call:
Dial (833) 325-0071 within the U.S.
Dial (720) 405-1612 outside the U.S.
Conference ID is 1697855
Webcast:
Live conference call webcast and replay
accessible at www.ligand.com
About Ligand Pharmaceuticals
Ligand is a revenue-generating biopharmaceutical company focused
on developing or acquiring technologies that help pharmaceutical
companies discover and develop medicines. Our business model
creates value for stockholders by providing a diversified portfolio
of biotech and pharmaceutical product revenue streams that are
supported by an efficient and low corporate cost structure. Our
goal is to offer investors an opportunity to participate in the
promise of the biotech industry in a profitable, diversified and
lower-risk business than a typical biotech company. Our business
model is based on doing what we do best: drug discovery,
early-stage drug development, product reformulation and partnering.
We partner with other pharmaceutical companies to leverage what
they do best (late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s
OmniAb® technology platform is a patent-protected transgenic animal
platform used in the discovery of fully human mono- and bispecific
therapeutic antibodies. The Captisol platform technology is a
patent-protected, chemically modified cyclodextrin with a structure
designed to optimize the solubility and stability of drugs. The
Vernalis Design Platform (VDP) integrates protein structure
determination and engineering, fragment screening and molecular
modeling, with medicinal chemistry, to help enable success in novel
drug discovery programs against highly-challenging targets. Ab
Initio™ technology and services for the design and preparation of
customized antigens enable the successful discovery of therapeutic
antibodies against difficult-to-access cellular targets. Ligand has
established multiple alliances, licenses and other business
relationships with the world’s leading pharmaceutical companies
including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier,
Gilead Sciences and Baxter International. For more information,
please visit www.ligand.com.
Follow Ligand on Twitter @Ligand_LGND.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200716006031/en/
Ligand Pharmaceuticals Incorporated Patrick O'Brien Email:
investors@ligand.com Phone: (858) 550-7893 Twitter:
@Ligand_LGND
LHA Investor Relations Bruce Voss Email: bvoss@lhai.com Phone:
(310) 691-7100
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024